| 產(chǎn)品名稱 |
Rotavirus reassortant |
| 商品貨號 |
B229230 |
| Classification |
Reoviridae, Rotavirus |
| Agent |
Rotavirus reassortant |
| Strain |
WI79(4+9) [WI79-4,9] |
| Applications |
vaccine production |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation |
Reassortant WI79-4,9, which contains gene segments 4 and 9 from the human rotavirus strain WI79, reassortants WI79-3,9 and WI79-4 were combined in a culture and treated with anti-bovine rotavirus serum. WI79-4,9 was then identified among the progeny and harvested from the culture. |
| Product Format |
frozen |
| Storage Conditions |
-70°C |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Comments |
-70C Propagate in cells fed with serum-free medium containing 0.5 ug/ml purified trypsin. |
| Effect on Host |
Yes, in vitro effects: Cytopathic effects (cell clumping followed by cell death and lysis) CPE is clumping followed by cell death and lysis |
| Recommended Host |
MA-104 cells (ATCC CRL-2378) Host of Choice: MA-104 (CRL-2378) Host Range: MA-104, CV-1, Vero MA-104 cells (ATCC CRL-2378); CV-1 cells (ATCC CCL-70); Vero cells (ATCC CCL-81) |
| Growth Conditions |
Temperature: 37.0°C Duration: 2-5 days at 37C |
| Cryopreservation |
Storage temperature: -70C |
| Name of Depositor |
Wistar Institute of Anatomy and Biology |
| U.S. Patent |
|
| U.S. Patent Number |
|
| Special Collection |
NCRR Contract |
| Source |
Reassortant WI79-4,9, which contains gene segments 4 and 9 from the human rotavirus strain WI79, reassortants WI79-3,9 and WI79-4 were combined in a culture and treated with anti-bovine rotavirus serum. WI79-4,9 was then identified among the progeny and harvested from the culture. |
| References |
Clark HF, et al. Rotavirus reassortant vaccine. US Patent 5,626,851 dated May 6 1997
|
